Commentary on the Recent FSH Collection: Known Knowns and Known Unknowns by Coss, Djurdjica
UC Riverside
UC Riverside Previously Published Works
Title











eScholarship.org Powered by the California Digital Library
University of California





Short title: FSH in reproduction and beyond 
 
Djurdjica Coss, Division of Biomedical Sciences; School of Medicine, University of 
California, Riverside; Riverside, CA 92521.  
 
 
Corresponding author: Djurdjica Coss  
Division of Biomedical Sciences,  
School of Medicine, 
University of California, Riverside;  
Riverside, California, USA 
















Click here to access/download;Manuscript (MUST INCLUDE
TITLE PAGE AND ABSTRACT);Commentary on the recent FSH
Abstract 
Follicle-stimulating hormone (FSH) is a dimeric glycoprotein secreted by the anterior pituitary 
gonadotrope, which is necessary for reproductive function in mammals. FSH primarily regulates 
granulosa cells and follicular growth in females, and Sertoli cell function in males. Since its 
identification in 1930s and sequencing in 1970s, significant progress has been made in elucidating 
its regulation and downstream function. Recent advances provide deeper insight into FSH 
synthesis and effects in the gonads, suggest potential roles in extragonadal tissues, and examine 
pharmacological approaches and clinical applications in infertility treatment, that now affects 18% 
of couples. These advances were discussed in detail in a number of reviews published in the last 
two years in Endocrinology. In this brief commentary, we summarize these reviews and point to 
the outstanding questions that should be answered in the near future to bridge a gap in our 










Follicle-stimulating hormone (FSH) is a gonadotropin hormone critical for reproductive 
function. It is synthesized and secreted from the anterior pituitary gonadotrope cells, primarily 
under the influence of hypothalamic GnRH neuropeptide, and ovarian or locally produced activin-
inhibin-follistatin system (reviewed recently in (1)). Structurally, FSH is a dimeric glycoprotein 
composed of a unique β subunit and a common  subunit shared with luteinizing hormone (LH) 
and thyroid-stimulating hormone. Contrary to LH, FSH secretion is not entirely regulated, and 
most of FSH is constitutively released. FSH in males stimulates Sertoli cell proliferation during 
development and maintains Sertoli cell function in adults, by inducing androgen binding protein 
that contributes to spermatogenesis through interaction with testosterone. In females, FSH 
stimulates growth of ovarian follicles and aromatase expression in follicle granulosa cells, which 
synthesizes estrogen. FSH deficiency in humans results in the absent or incomplete pubertal 
development in women, relatively normal pubertal development but azoospermia in men, and 
infertility in both women and men. Female mice deficient in FSH have a block in folliculogenesis 
prior to the antral stage resulting in infertility, while males have impaired reproductive function 
due to lower sperm count, but are not infertile (variety of FSH mouse models reviewed recently in 
(2, 3)).  
FSH concentration displays two temporally separate increases during female reproductive 
cycle, as opposed to LH which exhibits a single rise. During the rodent estrous cycle, a surge of 
GnRH during the afternoon of proestrus triggers a surge in both LH and FSH, resulting in ovulation 
of the mature follicle in response to LH. Several hours later, during the morning of estrus, a 
secondary FSH increase occurs, without a corresponding rise in LH. This secondary FSH rise is 
essential for follicular development for the subsequent cycle in rodents. In humans, FSH level 
increases in the late luteal phase through the mid-follicular phase of the menstrual cycle, in addition 
to the preovulatory rise, corresponding to the recruitment of a new cohort of follicles to the 
growing pool. During reproductive aging in females, rise in FSH is considered the hallmark of the 
reduction in the follicle reserve. The fall in inhibin B caused by the loss of follicles, coincides with 
the rise in FSH, supporting the primary role of inhibins in the negative feedback of FSH. 
Normal physiological function of FSH in women follows Goldilocks principle: low FSH 
impedes follicular growth, while high levels are associated with premature ovarian failure. Mouse 
models of FSH overexpression exhibit female infertility of unknown ovarian etiology, with 
follicles at various stages of development, lack of corpora lutea and the presence of large 
hemorrhagic and fluid-filled cysts (3). Premature ovarian failure (POF) is a disorder affecting 1% 
of reproductive age women that lose ovarian function before the age of 40, 70% of which are of 
idiopathic causes. POF can occur due to an accelerated loss of follicles, an inability of the 
remaining follicles to respond to ovulatory signals, an initially diminished ovarian reserve, or any 
combination thereof. Although it is possible that high FSH in POF is solely a consequence of 
reduced ovarian inhibin level, high FSH from any cause can potentially lead to the recruitment of 
a larger number of follicles into a growing pool in every cycle in younger women resulting in early 
depletion (1, 4). In fact, increased levels of FSH in the circulation, due to re-trafficking of FSH to 
the GnRH-regulated secretory pathway or to ectopic overexpression, resulted in significantly more 
corpora lutea, implicating higher FSH levels in greater follicle recruitment in these mouse models 
(3). Therefore, studies addressed in recent reviews all demonstrate that proper regulation of FSH 
concentration and function is critical for female fertility. In this brief commentary, we will 
summarize recent reviews published in Endocrinology, discussing FSH synthesis and function, 
and point to outstanding questions, answers to which will provide further insight into the 
physiology and pathophysiology of the reproductive system. 
Transcriptional regulation 
The unique FSH β-subunit provides biological specificity and is the limiting factor in the 
mature FSH synthesis, since α-subunit (GSU) is minimally regulated by hormones and is 
expressed at the sufficiently high basal level. While concentration of LH in the circulation is 
regulated at both the level of β-subunit transcription and GnRH-stimulated secretion, FSH 
concentration is regulated primarily at the level of β-subunit transcription, since FSH is 
constitutively secreted. FSH increases together with LH during the preovulatory surge and exhibits 
a separate, second increase that is necessary for folliculogenesis in humans and rodents. Changes 
in FSHβ mRNA (Fshb) levels precede changes in FSH concentration in the circulation. 
Transcription of Fshb is induced primarily by activin and GnRH. In mice lacking GnRH or GnRH 
receptor, FSH levels, as well as LH levels, are 60%-90% lower in males and females.  GnRH 
injection in rats with low endogenous GnRH increased FSH transcription 4-fold, comparable to 
the changes in FSH concentration in the circulation throughout the cycle. Signaling pathways and 
molecular mechanisms of this induction are reviewed by Stamatiades, et al., (5). Ex vivo studies 
using primary cells or studies using gonadotrope-derived model cell lines determined roles for 
calcium-activated pathways, calcineurin and CamKII, as well as for ERK1/2 MAPK and PKA 
pathways, in Fshb induction by GnRH. These pathways activate AP-1 or CREB transcription 
factors that replace repressors JDP2 or ICER on the Fshb promoter to activate Fshb transcription. 
Although whole body null mice of several of these players confirm their roles in maintaining FSH 
levels, studies using gonadotrope-specific deletions are either lacking or do not support findings 
in vitro. Future studies are needed to accurately determine the roles of identified signaling 
molecules and transcription factors in vivo and to establish mechanisms of GnRH regulation.   
Activin is a potent regulator of FSHβ gene expression and was originally identified as a 
component of ovarian follicular fluid that increased FSHβ synthesis and FSH secretion from 
pituitary gonadotrope cells. Expression of both intrapituitary follistatin and ovarian inhibin, 
inhibitors of activin, fluctuate during the estrous cycle in opposition to the levels of FSHβ mRNA, 
suggesting that bioavailability of activin, through changes in follistatin and/or inhibin levels, is a 
critical regulatory component of FSHβ synthesis. In particular, the secondary rise of FSH that is 
necessary for follicular development is dependent on activin since, both FSHβ mRNA and FSH 
levels in the blood can be reduced during the secondary rise in female rats infused with follistatin. 
Fshb regulation by activin / TGFβ family of proteins was reviewed by Fortin, et al., (6) and Ongaro, 
et al., (7). 
As with GnRH, studies using primary pituitary cells ex vivo or cell lines demonstrated that 
activins activate Fshb expression through a canonical type I and II receptors and Smad pathway. 
Smad3 is phosphorylated by the type I receptor, ALK4 primarily, dimerizes with Smad4, and 
translocates to the nucleus where it binds DNA either directly or via its interactions with Smad4 
and/or Foxl2 forkhead factor. Smad2, which can also be phosphorylated by activin signaling, is 
not critical for Fshb induction by activin. Although Smad3 links activin receptor to transcriptional 
activation, pituitary Fshb expression and fertility are unaffected in mice with a targeted deletion 
of Smad3 in gonadotropes, either alone or in combination with Smad2.  Since a truncated Smad3 
protein that lacks the DNA binding domain is expressed in the gonadotrope following 
gonadotrope-specific Cre cross, Smad3 may regulate Fshb transcription without direct DNA 
binding. Mice with Smad4 deletion in gonadotropes, on the other hand, are hypogonadal and 
females are subfertile with impaired ovarian follicle development. Both male and female Smad4 
conditional knockout mice exhibit diminished FSH levels and pituitary Fshb mRNA expression. 
Deletion of Foxl2 in gonadotropes using a Cre/lox approach also causes reductions in Fshb and 
subfertility, with females producing smaller and fewer litters. The reproductive phenotype of a 
double Smad4/Foxl2 conditional knockout mice is more dramatic and resembles FSHβ knockouts: 
females are infertile and lack estrous cyclicity, with arrested ovarian follicle development at an 
early antral stage. Their FSH deficiency is also more pronounced than in the single knockout mice. 
The same signaling pathway may be shared with BMP subfamily, which stimulates Fshb 
expression in vitro.  In particular, a role for BMP2, BMP4, BMP6 and BMP7 was proposed using 
cell lines (reviewed in (7)).  Although specific receptors for BMPs, ALK1, ALK2, ALK3, and 
ALK6, most often phosphorylate Smad1/5/8 instead of Smad2/3, Smad4 is a common dimerization 
partner. Roles of ALK2 and ALK3 have been examined with gonadotrope specific deletion and 
results demonstrate that they are dispensable for Fshb expression. Since ALK1 and ALK6 
expression is limited in gonadotropes, these results brought into question a role for BMPs in FSH 
regulation. In conclusion, studies demonstrate the necessity for Smad4 and Foxl2 is Fshb 
expression, however the roles of receptors (except for ALK2 and ALK3) and specific ligands, 
belonging to activin / TGF family, have not been determined. The variable effects of different 
ligands on Fshb may be a result of the complex interplay and crosstalk with the variety of type I 
and type II receptors. 
 
Post-transcriptional regulation, translation, glycosylation and secretion 
With an exception of glycosylation (reviewed in (8)) little is known about post-translational 
regulation, sorting and secretion of FSH. A couple of studies identified several micro-RNAs, 
miR-132 and miR-212 in particular, that regulate GnRH-stimulated FSH synthesis and secretion 
(reviewed in (5)). miR-125b, on the contrary, prevents GnRH-induced FSH synthesis and serves 
as a repressor. Importantly, in vivo studies are remaining to confirm their roles. Further, potential 
roles of other non-coding RNA species regulating FSH levels need to be addressed. Additionally, 
translational control of two other gonadotrope-specific genes, Lhb and Gnrhr, is beginning to 
emerge (reader is referred to the recent commentary by MacNicol, et al., (9)), but it is completely 
unexplored in regards to Fshb.   
FSH is an N-linked glycosylated protein, containing four N-acetylglucosamine residues (2 
on each subunit) linked to an amide group of an asparagine (Asn) amino acid in the peptide chain 
(reviewed in (8)). Thus, FSH exhibits macroheterogeneity, resulting from the absence of one or 
more of the N-glycans; and microheterogeneity, reflecting different branching of glycans and 
variable sialic acid content, resulting in size and charge variants. As opposed to LH, where sulfated 
glycans are more abundant, sialic acid predominates in FSH, although sulfate and phosphate may 
provide alternative negatively charged residues. Glycosylation is critical for bioactivity, due to the 
necessity of glycosylation for dimerization of α and β subunits, subsequent glycohormone 
secretion, regulation of half-life in the circulation and binding to its receptor in the gonads. In 
particular, mutation of either one of two FSHβ N-glycans significantly increases clearance and 
reduces in vivo biological activity, whereas mutation of both sites eliminates biological function 
due to dramatically accelerated clearance. FSH glycosylation changes during puberty, 
reproductive cycles and aging, implying hormonal regulation of glycosylation. Accordingly, the 
biological activity of circulating FSH can vary under changing physiological conditions. 
Interestingly, during reproductive ageing in women, ratio of partially glycosylated, lower 
molecular weight FSH21/18 to fully glycosylated FSH24 decreases. Several studies demonstrated 
that hypoglycosylated FSH21/18 is more potent in activating FSH signaling pathway than FSH24 
(reviewed in (2) and (10)). The mechanisms underlying carbohydrate modulation of FSH activity 
are poorly understood.  Although advances in mass spectrometry permit characterization of FSH 
glycan populations, positions, abundance, or linkages remain difficult to assess. However, 
understanding glycohormone regulation may be critical, since variants affect the biological activity 
of FSH, and glycosylations may vary in recombinant FSH preparations that are used in the clinic.  
FSH is largely released constitutively, while LH is released in a pulsatile manner, via a 
regulated secretory pathway following GnRH stimulation. LH contains a carboxy terminal 
heptapeptide that directs its secretion via the regulated pathway. LH and FSH appear to diverge 
early in the secretory pathway, rather than later in the trans-Golgi network, where most of protein 
sorting occurs. For that reason, FSH only granules are relatively rare in the pituitary, while LH-
only dense core granules can be observed, although majority of secretory granules contain both 
gonadotropins. However, it is still not clear if FSH associates with any chaperone or vesicular 
proteins in order to be sorted to the constitutive pathway. Questions also remain if there is any 
regulation of FSH secretion by hormones, such as steroids or activins, separately from their effects 
on β-subunit transcription. 
 
Receptor binding and signaling 
FSH binds and activates a 7-transmembrane domain, G-protein coupled receptor (FSHR) 
expressed in granulosa cells in ovaries and Sertoli cells in testes (reviewed in Ulloa-Aguirre, et al., 
(10) and Law, et al., (11)). In the granulosa cells, FSH regulates the expression of about 3800 genes 
that mediate proliferation and differentiation, and control the folliculogenesis from the preantral 
to the preovulatory stage. Such diverse functions are accomplished with complicated signaling 
pathways that are still not completely elucidated. FSHR can interact, directly or indirectly, with 
other receptors such as IGF-1 receptor and the epidermal growth factor receptor (EGFR), or 
heterodimerize with the LHR. Interactions with these other receptors alter or augment signaling 
pathways, but conditions under which these interactions occur in vivo are not clear. For example, 
FSHR activated PKA promotes inactivation of the MAPK phosphatase (MKP) dual specificity 
phosphatase DUSP6 which in turn elicits higher ERK phosphorylation by the EGFR. Crosstalk 
between LH and FSH receptors may be important for reproductive function, given that during the 
last stages of follicle development prior to ovulation, both receptors coexist in granulosa cells. 
FSHR primarily activates the Gs/cAMP/PKA pathway leading to FSH-responsive gene induction 
and sex steroid production. However, although this pathway canonically terminates in the 
activation of CREB transcription factor, FSH-responsive genes in humans are enriched in binding 
motifs for the GATA factors, and not CREB.  FSHR also activates several other signaling 
pathways via interaction with other G proteins, at least under certain conditions. FSHR stimulates 
Ca2+ mobilization in both granulosa and Sertoli cells via a variety of mechanisms. Besides 
possible interaction with Gq, since GPCRs can be promiscuous, APPL1 adaptor protein interacting 
with FSHR leads to calcium mobilization and to the activation of the protein kinase B/AKT anti-
apoptotic pathway. Alternatively, cAMP activates not only PKA, but EPAC as well, which leads 
to the activation of PKB/AKT and MAPK pathways. Activation of PKB/AKT is involved in 
proliferative pathways in both Sertoli and granulosa cells and in FSH-mediated protection of 
granulosa cells from atresia. Subsequent to G protein activation, FSHR itself is phosphorylated by 
GRKs at the intracellular tail, triggering association with β-arrestins that also leads to ERK1/2 
MAPK activation. ERK-activated mTOR pathway can induce the expression of FSH 
differentiative target genes, such as LHR, inhibin-, and Cyp19 aromatase. Most of these 
pathways were identified using ex vivo cells, cell lines, or reconstituted heterologous cells, while 
in vivo confirmation of their roles is unresolved, primarily owing to the lack of mouse models 
allowing cell-specific deletions. Greater understanding of FSH-mediated signaling network is of 
high physiological and clinical importance due to the crucial role for FSH in regulating mammalian 
reproduction.  
Elucidation of FSH signaling pathways could also lead to designing drug candidates that 
may activate selective signaling pathways in target cells. Several selective, nonpeptide, small 
molecules have been identified as FSH agonists (reviewed in Nataraja, et al., (12)). In addition, 
selective, nonpeptide antagonists to FSH receptors have been generated that inhibit ovulation in 
rats. Antagonists have the potential to offer a highly selective, nonsteroidal contraception methods 
with fewer side effects than the currently available steroid-based contraceptives. Of particular 
interest is potential for allosteric regulation of the receptor activity, meaning that the regulator 
interacts at one site to modulate interactions at a spatially distinct site of the same molecule. FSHRs 
can be modulated at allosteric sites that are away from the orthosteric, ligand-binging sites. This 
feature of FSHR signaling may allow development of ligands that specifically modulate effectors 
with desired effects. 
 
FSH function in extragonadal tissues 
FSHR is expressed in extragonadal tissues as well, especially in osteoclasts, adipocytes, 
chondrocytes, benign prostatic hyperplasia and prostate cancer, ovarian cancer and placenta.  
These findings imply a role for FSH in these tissues that has not been studied before, and more 
importantly, potential FSH effects in pathophysiology in instances with high or low FSH levels.  
During reproductive aging, women experience profound reductions in bone mineral 
density due to increased resorption rates. This phenomenon was considered to be a result of 
decreased estrogen, however new results point to the possible effects of increased FSH, which as 
mentioned above, is elevated in menopause. This phase of women’s life is associated with weight 
increase and visceral adiposity, as well as dysregulated energy homeostasis. Since FSHR is 
expressed in osteoclasts and adipocytes, it was postulated that increased FSH may be responsible 
for these effects of aging (review in (13) and (14)). In bone, FSH may increase osteoclast 
formation, function, and survival and thus, increased FSH in peri- and post-menopausal women 
may contribute to bone loss, since FSH can stimulate resorption by osteoclasts. Women with 
premature ovarian failure exhibit elevated FSH earlier, and regardless of causes of increased FSH 
as discussed above, they may face not only infertility, but increased risk of osteoporosis and heart 
disease, which is associated with increased visceral adiposity. Therefore, it is critical to address 
these outstanding questions.  
Furthermore, FSHR overexpression is observed in a variety of endocrine tissue cancers 
(reviewed in (15)). FSHR was expressed primarily on the endothelial cells in the peripheral tumor 
blood vessels. The available evidence indicates that epithelial FSHR promotes proliferation, 
migration, and invasion of ovarian, prostate, and breast cancer cells. Given the propensity for 
distant metastases, it is important to address a possible role of FSH in angiogenesis or metastatic 
potential of these tumors.  
Finally, in addition to tumor endothelial cells, FSHR protein was observed in normal 
vascular endothelium of the fetal vasculature within the chorionic villi, in glandular epithelium of 
the cervix, in proliferative and secretory endometrium, in muscle fibers and stroma of the 
myometrium, and in the placenta in pregnancy (reviewed in (16)). FSH in umbilical vein 
endothelial cells and in osteoclasts acts through a shorter FSHR isoform that lacks the C-terminal 
domain and does not stimulate cAMP production. This may explain the inability to detect FSHR 
in these tissues in earlier studies. Analyses of the wildtype and FSHR null feto-placental units 
revealed that the FSHR null placentas have fewer fetal vessels, revealing an important role for the 
FSHR in fetal vessel angiogenesis. This is reminiscent of its role in cancer angiogenesis. Normal 
placental development is necessary for the healthy pregnancy and impairment in placental function 
may result in fetal growth retardation and fetal death.  
Although these reports of extragonadal function of FSH are still controversial, they warrant 
examination using variety of approaches, potentially tissue-specific deletion of FSHR, to answer 
emerging questions. Studies reviewed herein, moreover, lend support for development of FSH 
antagonists for a treatment of osteoporosis, obesity, or endocrine tumors, in addition to new 
agonists for infertility discussed above.  Further investigations into functions of FSH beyond 
gonadal tissues is also critical to evaluate the consequence of dysregulated FSH levels.  
 
Conclusion  
Undoubtedly, we came a long way since the first evidence for the pituitary role in gonadal 
regulation was published in 1910. The pituitary–gonadal relationship as we know it today was 
described in 1930 (albeit authors called the corresponding hormones different names) and a year 
later gonadotropin hormones were extracted from the pituitary. Afterwards, in the mid-seventies 
gonadotropin hormones amino acid sequences were determined and two decades later genes 
cloned. Nonetheless, this commentary points to the outstanding questions that need to be answered 
to gain further insight in FSH function and regulation. Answers to these questions are crucial from 
the basic science perspective to increase our understanding of the regulation of reproductive 
function. Moreover, the future of infertility treatment, or other pathologies mentioned above, relies 
on our ability to fully elucidate the function of this hormone.   
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